Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

By pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any...

Full description

Bibliographic Details
Main Authors:	Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Cancers
Subjects:	interferon direct-acting antivirals hepatocellular carcinoma prognosis comparison
Online Access:	https://www.mdpi.com/2072-6694/12/11/3414

Similar Items

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
by: Pil Soo Sung, et al.
Published: (2020-04-01)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
by: Kwang Il Seo, et al.
Published: (2017-03-01)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
by: Olga Tronina, et al.
Published: (2023-03-01)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
by: Chen Z, et al.
Published: (2017-08-01)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
by: Yadong Wang, et al.
Published: (2022-07-01)

Treatment of hepatitis C virus infection: From therapy with interferon to direct-acting antivirals
by: Laura Lopera, et al.
Published: (2023-01-01)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
by: Hafiza Arooba Riaz, et al.
Published: (2023-05-01)

Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus
by: Evelyn J. Franco, et al.
Published: (2021-04-01)

Baculovirus Vectors Induce the Production of Interferons in Swine: Their Potential in the Development of Antiviral Strategies
by: Guido Nicolás Molina, et al.
Published: (2021-11-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Antiviral effects of interferon-stimulated genes in bats
by: Dan Zhang, et al.
Published: (2023-08-01)

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
by: Jae Seung Lee, et al.
Published: (2021-11-01)

Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro
by: Yu-Jin Kim, et al.
Published: (2020-07-01)

Emerging Role of Interferon-Induced Noncoding RNA in Innate Antiviral Immunity
by: Jie Min, et al.
Published: (2022-11-01)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
by: Taisuke Imamura, et al.
Published: (2022-04-01)

Crosstalk between Autophagy and Type I Interferon Responses in Innate Antiviral Immunity
by: Yu Tian, et al.
Published: (2019-02-01)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
by: Jucéli Márcia Hendges Sparvoli, et al.
Published: (2023-01-01)

Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report
by: Kenji Misaka, et al.
Published: (2016-10-01)

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
by: Tatsuya Minami, et al.
Published: (2021-06-01)

Interferons: the Nature, Mechanisms of Action and Clinical Use of Interferon Preparations
by: I.V. Dziublyk
Published: (2016-08-01)

Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
by: Pil Soo Sung, et al.
Published: (2018-09-01)

The regulation of antiviral activity of interferon epsilon
by: Fu-Rong Zhao, et al.
Published: (2022-10-01)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-10-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils
by: Ashley A. Stegelmeier, et al.
Published: (2021-04-01)

Editorial: Type III interferons: Emerging roles beyond antiviral barrier defense
by: Steeve Boulant, et al.
Published: (2022-09-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

Antiviral Activities of Interleukin-27: A Partner for Interferons?
by: Heather Amsden, et al.
Published: (2022-05-01)

Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation
by: Reina Sasaki, et al.
Published: (2016-05-01)

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan
by: Saba Khaliq, et al.
Published: (2018-11-01)

Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 Proteins
by: Cuncai Guo, et al.
Published: (2021-11-01)

Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan
by: M. N. Raza, et al.
Published: (2021-12-01)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
by: Roxana Nemteanu, et al.
Published: (2023-09-01)

Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma
by: Yumiko Nagao, et al.
Published: (2017-11-01)

Isolation and characterization of the mink interferon-epsilon gene and its antiviral activity
by: Hailing Zhang, et al.
Published: (2023-01-01)

Screening of interferon-stimulated genes against avian reovirus infection and mechanistic exploration of the antiviral activity of IFIT5
by: Sheng Wang, et al.
Published: (2022-09-01)

The role of interferon λ on antiviral immunity in upper respiratory tract
by: FAN Junyan, et al.
Published: (2022-01-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)